[go: up one dir, main page]

GB202117609D0 - 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia - Google Patents

2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia

Info

Publication number
GB202117609D0
GB202117609D0 GBGB2117609.4A GB202117609A GB202117609D0 GB 202117609 D0 GB202117609 D0 GB 202117609D0 GB 202117609 A GB202117609 A GB 202117609A GB 202117609 D0 GB202117609 D0 GB 202117609D0
Authority
GB
United Kingdom
Prior art keywords
oxothiazole
compositions
treatment
acute lymphoblastic
cell acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2117609.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coegin Pharma AB
Original Assignee
Coegin Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coegin Pharma AB filed Critical Coegin Pharma AB
Priority to GBGB2117609.4A priority Critical patent/GB202117609D0/en
Publication of GB202117609D0 publication Critical patent/GB202117609D0/en
Priority to PCT/EP2022/084623 priority patent/WO2023104809A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2117609.4A 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia Ceased GB202117609D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2117609.4A GB202117609D0 (en) 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
PCT/EP2022/084623 WO2023104809A2 (en) 2021-12-06 2022-12-06 2-oxothiazole compositions for treatment of t-cell acute lymphoblastic leukaemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2117609.4A GB202117609D0 (en) 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia

Publications (1)

Publication Number Publication Date
GB202117609D0 true GB202117609D0 (en) 2022-01-19

Family

ID=80080911

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2117609.4A Ceased GB202117609D0 (en) 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia

Country Status (2)

Country Link
GB (1) GB202117609D0 (en)
WO (1) WO2023104809A2 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02982A (en) 2009-10-02 2015-07-31 Avexxin As
CN105102438B (en) 2013-01-29 2019-04-30 埃维克辛公司 Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors
GB201806663D0 (en) 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
GB201906864D0 (en) 2019-05-15 2019-06-26 Avexxin As Combination therapy

Also Published As

Publication number Publication date
WO2023104809A2 (en) 2023-06-15
WO2023104809A3 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
IL308195A (en) Ras inhibitors for the treatment of cancer
IL300067A (en) Compositions and methods for treatment of cancers
IL309952A (en) Compositions and methods for treatment of melanoma
IL312583A (en) Composition for treatment and prevention of covid-19
IL308221A (en) Compositions and methods for the treatment of depression
PT3848024T (en) Compositions comprising amino acids for prevention and/or treatment of cancer
HUE073311T2 (en) Treatment of hyperinflammatory syndrome
GB202117609D0 (en) 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
IL287538A (en) Compositions and methods for treatment of cancer
PL3743043T3 (en) Pharmaceutical compositions for the treatment of postoperative pain
GB202316745D0 (en) Cd19car t-cell treatment of relapsed/regractory b-cell acute lymphoblastic leukaemia
ZA202212363B (en) Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of covid-19
GB202318794D0 (en) Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
GB202308063D0 (en) CD19CAR T-cell treatment of relapsed/refractory B-cell acute lymphoblastic leukaemia
CA3293827A1 (en) Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
HK40116340A (en) Composition for treatment and prevention of covid-19
IL313703A (en) Compositions for treatment of inflammation
PT4132587T (en) Ha-paclitaxel conjugate for treatment of mesothelioma
CA3278279A1 (en) Nootkatone for the treatment of gut or abdominal pain
GB202005986D0 (en) Methods and compositions for treating and combatting tuberulosis
IL314497A (en) Compositions and methods for covid-19 treatment
GB202316026D0 (en) Methods of prevention or treatment
GB202109830D0 (en) VCP inhibitors and uses thereof for treatment
EP4313077A4 (en) Combination for treatment of thromboinflammation
GB202315695D0 (en) TReatment of cariomyopathy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)